A Phase 1, Open-Label, Single-Dose, Parallel-Cohort Study to Evaluate the Pharmacokinetics of Divarasib in Subjects With Impaired Hepatic Function
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Divarasib (Primary)
- Indications Liver failure
- Focus Pharmacokinetics
- Sponsors Genentech
- 28 Jan 2025 Planned End Date changed from 30 Dec 2026 to 14 Jan 2027.
- 28 Jan 2025 Planned primary completion date changed from 11 May 2026 to 20 Oct 2026.
- 28 Jan 2025 Planned initiation date changed from 23 Dec 2024 to 31 Jan 2025.